Mineralocorticoid effects in the brain include the control of cardiovascular functions, induction of salt appetite, interaction with the vasoactive neuropeptides arginine vasopressin (AVP) and angiotensin II and development or aggravation of hypertension. In this regard, mineralocorticoids may play a pathogenic role in rats with a genetic form of hypertension (spontaneously hypertensive rats, SHR). Our objective was to compare the response of the hypothalamic vasopressinergic system to mineralocorticoid administration in SHR and control Wistar-Kyoto (WKY) rats. Sixteen-week-old male SHR showing a systolic blood pressure of 190 ± 5 mm Hg and normotensive WKY rats (130 ± 5 mm Hg) were treated subcutaneously with oil vehicle or a single 10-mg dose of deoxycorticosterone acetate (DOCA). After 2 h, rats were sacrificed and brains prepared for immunocytochemistry of Fos and vasopressin V1a receptor (V1aR) and for non-isotopic in situ hybridization of AVP mRNA. In the basal state, SHR demonstrated a higher number of AVP mRNA- and V1aR-immunopositive cells in the magnocellular division of the paraventricular hypothalamic nucleus (PVN) than WKY rats. After DOCA injection, SHR responded with a significant increase in both parameters with respect to vehicle-injected SHR. In WKY rats, DOCA was without effect on AVP mRNA although it increased the number of V1aR-positive cells. Changes in the number of Fos-positive nuclei were measured in the PVN, median preoptic nucleus (MnPO) and organum vasculosum of the lamina terminalis (OVLT), a circumventricular region showing anatomical connections with the PVN. In vehicle-injected rats, the PVN of SHR showed a higher number of Fos-positive nuclei than in WKY rats, whereas after DOCA treatment, a significant increment occurred in the OVLT but not in the PVN or MnPO of the SHR group only. These data suggest that the enhanced response of the vasopressinergic system to mineralocorticoids may contribute to the abnormal blood pressure of SHR.

Keywords:
Vasopressin, Vasopressin receptor, Fos, Paraventricular nucleus, Adrenal steroids, Hypertension, Preoptic nucleus, Organum vasculosum laminae terminalis
1.
Joels M, De Kloet ER: Control of neuronal excitability by corticosteroid hormones. Trends Neurosci 1992;15:25–30.
2.
McEwen BS, Lambdin LT, Rainbow TC, De Nicola AF: Aldosterone effects on salt appetite in adrenalectomized rats. Neuroendocrinology 1986;43:38–43.
3.
Mondadori C, Hausler A: Aldosterone receptors are involved in the mediation of the memory-enhancing effects of piracetam. Brain Res 1990;524:203–207.
4.
Ratka A, Sutanto W, Bloemers M, De Kloet ER: On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocrinology 1989;50:117–123.
5.
Ahima R, Krozowski Z, Harlan R: Type I corticosteroid receptor-like immunoreactivity in the rat CNS: Distribution and regulation by corticosteroids. J Comp Neurol 1991;313:522–538.
6.
Pietranera L, Saravia F, McEwen BS, Lucas LL, Johnson AK, De Nicola AF: Changes in Fos expression in various brain regions during deoxycorticosterone acetate treatment: relation to salt appetite, vasopressin mRNA and the mineralocorticoid receptor. Neuroendocrinology 2001;74:396–406.
7.
Boldyreff B, Wehling M: Rapid aldosterone actions: from the membrane to signalling cascades to gene transcription and physiological effects. J Steroid Biochem Mol Biol 2003;85:375–381.
8.
Lucas LR, Pompei P, McEwen BS: Effects of deoxycorticosterone acetate and diazepam on neuropeptidergic neurons in rat striatum. Neuroreport 1997;8:811–816.
9.
Van den Berg DTWM, De Jong W, De Kloet ER: Mineralocorticoid antagonists inhibit stress-induced blood pressure response after repeated daily warming. Am J Physiol 1994;267:E921–E926.
10.
Hashimoto K, Makino S, Hirasawa R, Takao T, Sugawara M, Murakami K, Ono K, Ota Z: Abnormalities in the hypothalamic-pituitary-adrenal axis in spontaneously hypertensive rats during development of hypertension. Endocrinology 1989;125:1161–1167.
11.
Gomez F, Lahmame A. De Kloet ER, Armario A: Hypothalamic-pituitary-adrenal response to chronic stress in five inbred rat strains: Differential responses are mainly located at the adrenocortical level. Neuroendocrinology 1996;63:327–337.
12.
Rahmouni K, Barthelmebs M, Grima M, Imbs JL, De Jong W: Involvement of brain mineralocorticoid receptor in salt-enhanced hypertension in spontaneously hypertensive rats. Hypertension 2001;38:902–906.
13.
Kenyon CJ, De Conti GA, Cupolo NA, Morris DJ: The role of aldosterone in the development of hypertension in spontaneously hypertensive rats. Endocrinology 1981;109:1841–1845.
14.
Sutanto W, Oitzl MS, Rots NY, Schobitz B, Van den Berg DT, Van Dijken HH, Mos J, Cools AR, Tilders FJ, Koolhaas JM: Corticosteroid receptor plasticity in the central nervous system of various rat models. Endocr Regul 1992;26:111–118.
15.
Konishi A, Tazawa C, Miki Y, Darnel AD, Suzuki T, Ohta Y, Suzuki T, Tabayashi K, Sasano H: The possible roles of mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type 2 in cardiac fibrosis in the spontaneously hypertensive rat. J Steroid Biochem Mol Biol 2003:85:439–442.
16.
Mirshahi M, Nicolas C, Agarwal MK: Enhanced activation of the mineralocorticoid receptor in genetically hypertensive rats. Biochem Biophys Res Commun 1998;244:120–125.
17.
Imaki T, Naruse M, Harada S, Chikada N, Nakahuma N, Yoshimoto T, Demura H: Stress-induced changes of gene expression in the paraventricular nucleus is enhanced in spontaneously hypertensive rats. J Neuroendocrinol 1998;10:633–643.
18.
Ciriello J, Kline RL, Zhang TX, Caverson MM: Lesions of the paraventricular nucleus after the development of spontaneous hypertension in the rat. Brain Res 1984;310:355–359.
19.
Allen AM: Inhibition of the hypothalamic paraventricular nucleus in spontaneously hypertensive rats dramatically reduces sympathetic vasomotor tone. Hypertension 2002;39:275–280.
20.
Antoni FA: Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 1993;14:76–122.
21.
De Wandener HE: The hypothalamus and hypertension. Physiol Rev 2001;81:1599–1658.
22.
Krukoff TL, MacTavish D, Jhamandas JH: Hypertensive rats exhibit heightened expression of corticotropin-releasing factor in activated central neurons in response to restraint stress. Brain Res Mol Brain Res 1999;65:70–79.
23.
Goncharuk VD, Van Heerikhuize J, Swaab D, Buijs R: Paraventricular nucleus of the human hypothalamus in primary hypertension: activation of corticotropin-releasing hormone neurons. J Comp Neurol 2002;443:321–331.
24.
Van Tol HH, van den Buuse M, de Jong W, Burbach JP: Vasopressin and oxytocin gene expression in the supraoptic and paraventricular nucleus of the spontaneously hypertensive rat during development of hypertension. Brain Res 1988;464:303–311.
25.
Burrell LM, Phillips PA, Risvanis J, Aldred KL, Hutchins AM, Johnston CI: Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism. Hypertension 1995;26:828–834.
26.
Hurbin A, Boissin-Agasse L, Orcel H, Rabié A, Joux N, Desarrménien G, Richard P, Moos FC: The V1a and V1b, but not the V2, vasopressin receptor genes are expressed in the supraoptic nucleus of the rat hypothalamus, and the transcripts are essentially colocalized in the vasopressinergic magnocellular neurons. Endocrinology 1998;139:4701–4707.
27.
Hurbin A, Orcel H, Alonso G, Moos F, Rabié A: The vasopressin receptors colocalize with vasopressin in the magnocellular neurons of the supraoptic nucleus and are modulated by water balance. Endocrinology 2002;143:456–466.
28.
Grillo C, Saravia F, Ferrini M, Piroli G, Roig P, Garcia S, de Kloet ER, De Nicola AF: Increased expression of magnocellular vasopressin mRNA in rats with DOCA-induced salt appetite. Neuroendocrinology 1998;68:105–115.
29.
Saravia F, Grillo C, Ferrini M, Roig P, Lima A, de Kloet ER, De Nicola AF: Changes of hypothalamic and plasma vasopressin in rats with deoxycorticosterone-acetate induced salt appetite. J Steroid Biochem Mol Biol 1999;70:47–57.
30.
Swords BH, Wyss JM, Berecek KH: Central vasopressin receptors are upregulated by deoxycorticosterone acetate. Brain Res 1991;559:10–16.
31.
Kovács K: c-Fos as a transcription factor: a stressful (re)view from a functional map. Neurochem Int 1998;33:287–297.
32.
Landry M, Roche D: In situ hybridization: Methods and application to the multiple labelling. EMBO Course on Basic Methods in Molecular Neuroanatomy. Université Pierre & Marie Curie CNRS, 1994.
33.
Ivell R, Richter D: Structure and comparison of the oxytocin and vasopressin genes from the rat. Proc Natl Acad Sci USA 1984;81:2006–2010.
34.
Saravia FE, Gonzalez SL, Roig P, Alves V, Homo-Delarche F, De Nicola AF: Diabetes increases the expression of hypothalamic neuropeptides in a spontaneous model of type 1 diabetes, the nonobese diabetic mouse. Cell Mol Neurobiol 2001;21:15–28.
35.
Kc P, Haxhiu MA, Tolentino-Silva FP, Wu M, Trouth CO, Mack SO: Paraventricular vasopressin-containing neurons project to brain stem and spinal cord respiratory-related sites. Respir Physiol Neurobiol 2002;133:75–88.
36.
Xu Z, Johnson AK: Central renin injections: Effects on drinking and expression of immediate early genes. Brain Res 1998;782:24–35.
37.
Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. Sydney, Academic Press, 1982.
38.
Gutkind JS, Kurihara M, Castren E, Saavedra JM: Increased concentration of angiotensin II binding sites in selected brain areas of spontaneously hypertensive rats. J Hypertens 1988;6:79–84.
39.
Chamorro V, Moreno JM, Wangensteen R, Sainz J, Rodrigeuz-Gomez I, Osuna A, Vargas F: Effects of deoxycorticosterone on renal vascular reactivity and flow-pressure curve in spontaneously hypertensive rats. J Physiol Pharmacol 2004;55:17–26.
40.
Miyakubo H, Hayashi Y, Tanaka J: Enhanced response of subfornical organ neurons projecting to the hypothalamic paraventricular nucleus to angiotensin II in spontaneously hypertensive rats. Anat Neurosci 2002;95:131–136.
41.
Yongue BG, Angulo JA, McEwen BS, Myers MM: Brain and liver angiotensinogen messenger RNA in genetic hypertensive and normotensive rats. Hypertension 1991;17:485–491.
42.
Phillips MI: Angiotensin in the brain. Annu Rev Physiol 1987;49:413–435.
43.
Hügin-Flores ME, Steimer T, Auber ML, Schulz P: Mineralo- and glucocorticoid receptor mRNAs are differently regulated by corticosterone in the rat hippocampus and anterior pituitary. Neuroendocrinology 2004;79:174–184.
44.
Birmingham MK, Sar M, Stumpf WE: Localization of aldosterone and corticosterone in the central nervous system, assessed by quantitative autoradiography. Neurochem Res 1984;9:331–348.
45.
De Kloet ER, Sutanto W, van den Bergh D, Carey MP, van Haarst AD, Hornsby CD, Meijer OC, Rots NY, Oitzl M: Brain mineralocorticoid receptor diversity: Functional implications. J Steroid Biochem Mol Biol 1993;47:183–190.
46.
Sakai RR, McEwen BS, Fluharty SJ, Na LY: The amygdala: Site of genomic and nongenomic arousal of aldosterone-induced salt intake. Kidney Int 2000;57:1337–1345.
47.
Lucas LR, Pompei P, McEwen BS: Salt appetite in salt-replete rats: Involvement of mesolimbic structures in deoxycorticosterone-induced salt craving behaviour. Neuroendocrinology 2000;71:386–395.
48.
Johnson AK, Cunningham JT, Thunhorst RL: Integrative role of the lamina terminalis in the regulation of cardiovascular and body fluid homeostasis. Clin Exp Pharmacol Physiol 1996;23:183–191.
49.
McKinley MJ, Gerstberger R, Mathai ML, Oldfield BJ, Schmid H: The lamina terminalis and its role in fluid and electrolyte homeostasis. J Clin Neurosci 1999;6:289–301.
50.
Horn EM, Shonis CA, Holzwarth MA, Waldrop TG: Decrease in glutamic acid decarboxylase level in the hypothalamus of spontaneously hypertensive rats. J Hypertension 1998;16:625–633.
51.
Angulo JA, Ledoux M, McEwen BS: Genomic effects of cold and isolation stress on magnocellular vasopressin mRNA-containing cells in the hypothalamus of the rat. J Neurochem 1991;23:2033–2038.
52.
Sabbatini M, Strocchi P, Vitaioli L, Amenta P: The hippocampus in spontaneously hypertensive rats: A quantitative microanatomical study. Neuroscience 2000;100:251–258.
53.
Perfilieva E, Risedal A, Nyberg J, Johansson BB, Eriksson PS: Gender and strain influence on neurogenesis in dentate gyrus of young rats. J Cereb Blood Flow Metab 2001;21:211–217.
54.
Herman JP, Schafer MK, Young EA, Thompson R, Doiuglass J, Akil H, Watson SJ: Evidence for hippocampal regulation of neuroendocrine neurones of the hypothalamic-pituitary-adrenocortical axis. J Neurosci 1989;9:3071–3082.
55.
Sofroniew MV, Schrel U: Evidence for a direct projection from oxytocin and vasopressin neurons in the hypothalamic paraventricular nucleus to the medulla oblongata: Immunohistochemical visualization of both the horseradish peroxidase transported and the peptide produced by the same neurons. Neurosci Lett 1981;22:211–214.
56.
Rowland NE, Bain-Han L, Fregly MJ, Smith GC: Fos induced in brain of spontaneously hypertensive rats by angiotensin II and co-localization with AT-1 receptors. Brain Res 1995;675:127–134.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.